tuberculosis infection of patients with rheumatic diseases
Conditions
Interventions
HP (6w) Group :Isoniazid (600mg, biw) and rifapentine (600mg, biw) for 6 weeks
Modified 3HP (12 weeks) Group:Isoniazid (300mg, qd) and rifapentine (450mg, biw) for 12 weeks
Sponsors
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Diagnosed with any types of rheumatic disease; (2) Aged = 18 years old; (3) Medication meet any of the following requirements: ? Currently treated with glucocorticoids at a dosage equivalent to 15mg prednisone daily or more; ? Using any of the following immunosupressants: methotrexate, cyclophosphamide, mycophenolate mofetil, cyclosporine A, azathioprine, tacrolimus, leflunomide, iguratimod, tripterygium glycosides; ? Preparing to use any of following biologics: etanercept, infliximab, adalimumab, golimumab, beritan, telitacicept, tofacitinib, baricitinib; (4) There is currently no evidence of active tuberculosis or suspected active tuberculosis; (5) No history of anti-tuberculosis treatment in the past 2 years; (6) Positive results of IGRAs.
Exclusion criteria
Exclusion criteria: (1) Combined with malignant tumors; (2) Accompanied by severe organ failure; (3) Patients whose expected survival time is less than 1 year; (4) HIV-positive; (5) History of Isoniazid or Rifapentine allergy; (6) Women during pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Drug discontinuation rate due to serious adverse events or tuberculosis reactivation;Incidence of active tuberculosis; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of tolerable adverse events;Drug compliance; | — |
Countries
P.R.China
Contacts
Public ContactXiaoqing Liu
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Outcome results
None listed